If you or a loved one has relapsed or refractory multiple myeloma, a newly approved treatment combination, iberdomide paired with daratumumab and dexamethasone, is opening up a fresh option after prior therapy stops working.
This drug class, called a CELMoD (cereblon E3 ligase modulator), is the first of its kind approved for myeloma, and it comes with real benefits as well as specific precautions around blood clots, infections, and pregnancy risk that patients and caregivers need to know before starting treatment. For background on how myeloma is first identified, see our related read on early symptoms of blood cancers and our guide to chemotherapy side effects and recovery.
Key Takeaways
• A new oral drug class called CELMoDs (cereblon E3 ligase modulators) has received FDA accelerated approval for relapsed/refractory multiple myeloma, the first such approval of its kind.
• The new combination (iberdomide plus daratumumab plus dexamethasone) nearly doubled the rate of deep, MRD-negative remission compared to a standard regimen in clinical trials.
• It carries boxed warnings for blood clots and harm to a developing pregnancy, meaning strict monitoring and contraception precautions are required.
• Low blood counts and infections are common side effects that need regular blood work and prompt reporting of fever or illness.
• This treatment is for patients who have already tried at least one prior line of therapy; it is not a first-line option.
• Talk to your oncologist about whether your prior treatment history and current health make you a candidate.
What Is Multiple Myeloma and Why Does It Keep Coming Back?
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell made in the bone marrow that normally produces antibodies to fight infection. In myeloma, abnormal plasma cells multiply out of control, crowding out healthy blood cells and often causing bone damage, kidney problems, anemia, and a weakened immune system. It is typically a relapsing condition. Most patients respond to initial treatment, but the disease often returns, requiring new lines of therapy over time as earlier drugs stop working or the cancer develops resistance to them. This is exactly the situation the newest drug combinations are designed to address: what to do when myeloma comes back after earlier treatment.
1. What Is CELMoD Therapy and How Does Iberdomide Treat Multiple Myeloma?
Iberdomide belongs to a brand new drug class called CELMoDs, which work by targeting and breaking down specific proteins inside myeloma cells. This slows cancer growth, triggers cancer cell death, and also boosts the immune system’s ability to attack the remaining cancer cells. It is taken as a daily pill in combination with daratumumab (an antibody infusion) and dexamethasone (a steroid).
• Ask your oncologist whether you meet the criteria: at least one prior treatment line that included both a proteasome inhibitor and an immunomodulatory drug.
• Understand that this is an oral medication taken alongside infusion based therapy, so your treatment schedule will involve both clinic visits and at home pills.
• Clarify how long treatment is expected to continue. Generally, it continues until the disease progresses or side effects become unacceptable.
For full prescribing and safety details, refer to the FDA’s official approval announcement.
Can New Multiple Myeloma Drugs Like Iberdomide Cure the Disease?
Not exactly, and this is an important myth to clear up. The goal of this combination is deep, sustained remission (measured as “MRD-negative complete response,” meaning no detectable cancer cells remain even with sensitive testing) rather than an outright cure. In trials, this deeper remission was achieved by roughly 4 in 10 patients on the new combination, compared to about 2 in 10 on the older comparator regimen. Deeper remission is linked to better long-term outcomes, but multiple myeloma is still generally considered a manageable, chronic cancer rather than a curable one.
2. Why Does the New Myeloma Treatment Combination Increase Blood Clot Risk?
One of the most serious risks flagged for this drug combination is an increased chance of blood clots in the veins and arteries, serious enough that it carries an FDA boxed warning, the strongest safety warning a medication can carry. The exact mechanism is linked to how CELMoDs and immune-modulating drugs affect clotting factors and blood vessel walls.
• Report any leg swelling, pain, warmth, sudden shortness of breath, or chest pain to your care team immediately.
• Your doctor may prescribe blood thinning medication or aspirin alongside treatment as a preventive measure.
• Stay as physically active as your condition allows, since prolonged immobility raises clotting risk.
3. Why Are Infections and Low Blood Counts Common During Iberdomide Treatment?
Because CELMoD therapy affects the immune system and bone marrow, low white blood cell counts (neutropenia) and infections are common, occurring in a large majority of patients in clinical trials. This happens because the same pathways that help the drug attack cancer cells can also temporarily suppress the bone marrow’s production of healthy blood cells.
• Expect frequent blood tests to monitor your white cell, red cell, and platelet counts throughout treatment.
• Avoid close contact with people who are visibly sick, and stay current on recommended vaccinations as advised by your oncologist.
• Report fever, chills, cough, or any new signs of infection right away. Don’t wait for your next scheduled visit.
The National Cancer Institute provides general guidance on managing infection risk during cancer treatment.
Does a Low Blood Count During Myeloma Treatment Always Mean the Treatment Is Failing?
No, this is a common misconception. Low blood counts are usually a side effect of how the drugs work on the bone marrow, not a sign that the cancer is getting worse. Your care team will often pause treatment, adjust the dose, or use supportive medications to bring counts back up before resuming.
4. Can Iberdomide Be Taken During Pregnancy or While Trying to Conceive?
No. Iberdomide carries a boxed warning for embryo-fetal toxicity, meaning it can cause serious harm to a developing pregnancy. Because of this risk, the drug is only available through a restricted safety program with built-in pregnancy testing and counseling requirements.
• Patients who can become pregnant must use effective contraception during treatment and for a defined period afterward, as directed by their oncologist.
• The medication is dispensed only through a certified restricted distribution program that includes pregnancy testing and counseling.
• Discuss fertility preservation options with your care team before starting treatment if this is a concern.
5. Does Long-Term Multiple Myeloma Treatment Increase the Risk of Other Cancers?
Ongoing monitoring for secondary primary cancers is recommended for patients on this therapy, as with several other myeloma treatments that modulate the immune system over long periods. This surveillance is a precaution rather than a certainty of harm, and it reflects how carefully newer immune modulating drugs are tracked after approval.
• Keep all scheduled follow-up appointments, even once you’re feeling well.
• Report any unusual new symptoms, such as unexplained weight loss, persistent pain, or new lumps, promptly.
• Ask your oncologist what specific screening schedule applies to you based on your treatment history.
How Do Doctors Diagnose and Monitor Multiple Myeloma Before and During Treatment?
Diagnosis and ongoing monitoring typically involve a combination of blood and bone marrow tests:
• Blood tests check for abnormal proteins (M-protein), calcium levels, kidney function, and blood cell counts.
• Urine tests look for Bence Jones proteins.
• Bone marrow biopsy confirms the presence and percentage of abnormal plasma cells.
• Imaging such as X-rays, MRI, or PET-CT scans checks for bone damage.
• MRD testing is a highly sensitive test used after treatment to check for any remaining trace of disease, increasingly used to guide decisions about newer therapies like the CELMoD combination.
Early signs worth mentioning to your doctor include unexplained bone pain, especially in the back or ribs, persistent fatigue, frequent infections, and unexplained weight loss.
What to avoid: Don’t adjust or stop any myeloma medication on your own, even if you feel better. Stopping treatment prematurely can allow the disease to progress. Avoid over the counter supplements or herbal products without checking with your oncologist, as some can interact with cancer therapies or worsen blood clotting risk.
Is the New Multiple Myeloma Treatment Combination Right for You?
Newer combinations like iberdomide plus daratumumab represent real progress for patients whose myeloma has returned after standard treatment, but they are not a one size fits all solution. The right treatment depends on your prior therapies, current organ function, clotting risk, and personal goals of care. This is a decision best made together with a medical oncologist who can review your full treatment history.
Consult a medical oncologist if you or a loved one is experiencing:
• Bone pain that doesn’t improve with rest
• Unexplained fatigue or repeated infections
• A myeloma relapse after previous treatment
• Questions about whether new treatment options apply to your case
What Are the Warning Signs of a Medical Emergency During Multiple Myeloma Treatment?
Certain symptoms during multiple myeloma treatment need immediate medical attention rather than waiting for a scheduled appointment:
• Sudden shortness of breath or chest pain, which can signal a blood clot
• Leg swelling, redness, or pain, especially in one leg
• High fever or chills
• Severe weakness, confusion, or fainting
• Uncontrolled bleeding or unusual bruising
If any of these occur, go to the nearest emergency department or call emergency services right away.
Medically Reviewed & Approved By
Dr. Namratha Sai Reddy
This article has been medically reviewed for accuracy as of September 2026 and reflects the most current FDA approved treatment information available at the time of publication.
Medical References
1. U.S. Food and Drug Administration. FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma. Published August 13, 2026.
2. International Myeloma Foundation. What Is Iberdomide? myeloma.org.
3. Pharmacy Times. FDA Grants Accelerated Approval to Iberdomide Combination for Multiple Myeloma. August 2026.
4. Oncology Nursing News. What Nurses Need to Know About FDA Approved Iberdomide in Multiple Myeloma. August 19, 2026.
5. National Cancer Institute. Multiple Myeloma, Patient Version. cancer.gov.
6. American Cancer Society. Multiple Myeloma: Early Detection, Diagnosis, and Staging.
Frequently Asked Questions
1. What is the new multiple myeloma treatment combination approved in 2026?
It’s iberdomide (brand name Zenbexus) combined with daratumumab and dexamethasone, the first CELMoD based regimen approved for multiple myeloma, intended for patients who’ve had at least one prior treatment.
2. Who is eligible for this new multiple myeloma treatment?
Adults with multiple myeloma that has relapsed or stopped responding after at least one prior line of therapy that included both a proteasome inhibitor and an immunomodulatory drug.
3. Is iberdomide a cure for multiple myeloma?
No. It’s designed to achieve deep, long lasting remission, not a permanent cure. Multiple myeloma is generally managed as a chronic, relapsing cancer.
4. What are the main precautions with this new myeloma drug combination?
The key precautions are increased risk of blood clots, low blood counts and infections, and serious risk to a developing pregnancy, all of which require close monitoring.
5. Can I take iberdomide if I’m pregnant or planning to become pregnant?
No. Iberdomide can cause serious harm to a developing pregnancy and is contraindicated during pregnancy. Effective contraception is required during and after treatment as directed by your doctor.
6. How is the new multiple myeloma combination treatment taken?
Iberdomide is an oral pill taken on a cycle based schedule, combined with daratumumab given as a subcutaneous injection and dexamethasone taken orally.
7. What side effects should multiple myeloma patients watch for with this treatment?
Low white blood cell counts, increased risk of infection, fatigue, and blood clot symptoms such as leg swelling or sudden shortness of breath are the most important to monitor.
8. How do doctors know if the new myeloma treatment is working?
Through regular blood and bone marrow testing, including sensitive MRD (minimal residual disease) testing, which can detect very small amounts of remaining cancer.
9. Should I stop my current myeloma medication to switch to this new combination?
Never stop or switch myeloma treatment without your oncologist’s guidance. Doing so can allow the disease to progress. Discuss any changes with your care team first.
10. When should a multiple myeloma patient seek urgent medical care during treatment?
Contact your care team or seek emergency care immediately for signs of a blood clot such as leg swelling, chest pain, or shortness of breath, as well as high fever or severe bleeding.